The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients.
We investigated the effects of a 5-hydroxytryptamine (5-HT) 1A receptor gene polymorphism on the clinical response to fluvoxamine (FLV) in 65 depressed outpatients who gave written consent to participate in the study. Patients visited every 2 weeks after the first examination until the week 12 end point and were evaluated by the 17-item Hamilton Rating Scale for Depression (HAM-D-17) at each visit. FLV dose was changed in response to their clinical symptoms. The Gly272Asp polymorphism of the 5-HT1A receptor gene was identified by a PCR method. The subjects with the Asp allele had a significantly higher % reduction in the HAM-D-17 score than those with the Gly/Gly genotype at week 2 (P=0.009), week 6 (P=0.036), and week 12 (P=0.031). There was a significant difference in the genotype distribution between the responders and nonresponders. These results suggest that the Gly272Asp polymorphism of the 5-HT1A receptor gene may predict the response to FLV.
Suzuki
Y
Y
Department of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Sawamura
K
K
Someya
T
T
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D001224:Aspartic Acid / Q000235:genetics; D003866:Depressive Disorder / Q000188:drug therapy / Q000235:genetics*; D005260:Female; D016666:Fluvoxamine / Q000627:therapeutic use*; D005838:Genotype; D005998:Glycine / Q000235:genetics; D006801:Humans; D008297:Male; D044282:Receptor, Serotonin, 5-HT1A / Q000235:genetics*; D016896:Treatment Outcome
D018687:Antidepressive Agents, Second-Generation; D044282:Receptor, Serotonin, 5-HT1A; D001224:Aspartic Acid; D016666:Fluvoxamine; D005998:Glycine